Veteran left-hander Yuvraj Singh was on Sunday (13) dropped from the Indian squad for the limited overs series against Sri Lanka in what could possibly signal an end to his illustrious international career.
A two-time World Cup winner and one of India's finest limited overs exponent, the 35 year old Yuvraj's place was always under the scanner.
After a 50 against Pakistan in the Champions Trophy opener, Yuvraj hardly did anything notable as his last seven ODI innings fetched him only 162 runs.
A senior BCCI official, who is privy to selection policy said that Yuvraj is no longer in contention for the 2019 World Cup in England and Wales.
"His batting has lost sting. He rarely bowls and his fielding has gone down a few notches. If we have to prepare a team for 2019 World Cup, we had to take a call now. In case of Mahendra Singh Dhoni, we still don't have replacement but Yuvraj's place has multiple contenders," the official, who can't come on record said on Sunday.
Yuvraj has scored over 8000 runs in 304 ODIs, apart from playing 40 Tests and 58 T20 Internationals.
Mahendra Singh Dhoni's selection also indicates, he is in scheme of things for the 2019 World Cup in England.
Another player dropped from the squad that went to West Indies is young keeper-batsman Rishabh Pant, who has been replaced by KL Rahul, who is also a decent wicketkeeper. Kedar Jadhav is also good behind the stumps.
Dinesh Karthik, who did a decent job in the West Indies was also dropped since he was picked as Manish Pandey's replacement.
The national selection committee decided to rest all senior bowlers - fast bowlers Mohammed Shami, Umesh Yadav along with spinners Ravichandran Ashwin and Ravindra Jadeja.
Jasprit Bumrah makes a comeback after much needed rest while rookie Mumbai pacer Shardul Thakur has also been included in the side.
The spin department will be relatively young with left-arm spinner Axar Patel and leg-spinner Yuzvendra Chahal to support chinaman Kuldeep Yadav.
Fit again India A captain Pandey has been recalled after leading the side to tri-nation series win in South Africa.
He scored 307 runs in five games and was dismissed only once.
Rahul was also an automatic choice once he is fit. After twin 50s in Tests, there was no debate on his return.
As far as Shardul's selection, he is among the reserve pool of fast bowlers whom selectors would ideally like to try out against a weak team like Sri Lanka.
Veteran Suresh Raina remains on standby as he has not played ODIs since 2015.
UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.
Investment gap
Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.
Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.
Richard Torbett, ABPI Chief Executive, noted “The UK can lead globally in medicines and vaccines, unlocking billions in R&D investment and improving patient access but only if barriers are removed and innovation rewarded.”
The UK invests just 9% of healthcare spending in medicines, compared with 17% in Spain, and only 37% of new medicines are made fully available for their licensed indications, compared to 90% in Germany.
Expert reviews
Shailesh Solanki, executive editor of Pharmacy Business, pointed that “The government’s own review shows the sector is underfunded by about £2 billion per year. To make transformation a reality, this gap must be closed with clear plans for investment in people, premises and technology.”
The National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold £20,000 to £30,000 per Quality-Adjusted Life Year (QALY) — has remained unchanged for over two decades, delaying or deterring new medicine launches. Raising it is viewed as vital to attracting foreign investment, expanding patient access, and maintaining the UK’s global standing in life sciences.
Guy Oliver, General Manager for Bristol Myers Squibb UK and Ireland, noted that " the current VPAG rate is leaving UK patients behind other countries, forcing cuts to NHS partnerships, clinical trials, and workforce despite government growth ambitions".
Reeves’ push for reform, supported by the ABPI’s Competitiveness Framework, underlines Britain’s intent to stay a leading hub for pharmaceutical innovation while ensuring NHS patients will gain faster access to new treatments.
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.